PDS Biotechnology Files 8-K

Ticker: PDSB · Form: 8-K · Filed: Mar 13, 2025 · CIK: 1472091

Pds Biotechnology Corp 8-K Filing Summary
FieldDetail
CompanyPds Biotechnology Corp (PDSB)
Form Type8-K
Filed DateMar 13, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, financials

TL;DR

PDS Biotech filed an 8-K on March 13, 2025, for routine corporate updates.

AI Summary

PDS Biotechnology Corporation filed an 8-K on March 13, 2025, reporting on other events and financial statements. The company, formerly known as Edge Therapeutics, Inc., is incorporated in Delaware and headquartered in Princeton, NJ.

Why It Matters

This filing indicates routine corporate reporting, providing updates on company events and financial disclosures for investors and regulatory bodies.

Risk Assessment

Risk Level: low — This is a standard 8-K filing for corporate events and financial statements, not indicating any specific new risks.

Key Players & Entities

  • PDS Biotechnology Corporation (company) — Registrant
  • Edge Therapeutics, Inc. (company) — Former Company Name
  • March 13, 2025 (date) — Date of Report
  • Princeton, NJ (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of March 13, 2025.

What is the exact name of the registrant?

The exact name of the registrant is PDS Biotechnology Corporation.

When was PDS Biotechnology Corporation incorporated?

PDS Biotechnology Corporation was incorporated in Delaware.

What is the company's principal executive office address?

The company's principal executive office is located at 303A College Road East, Princeton, NJ 08540.

What was the company's former name?

The company's former name was Edge Therapeutics, Inc.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 13, 2025 regarding PDS Biotechnology Corp (PDSB).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.